Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:gene
|
| gptkbp:associatedWith |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:cause |
constitutive ALK kinase activation
|
| gptkbp:commonIn |
never-smokers with NSCLC
|
| gptkbp:detects |
gptkb:FISH
gptkb:RT-PCR gptkb:NGS |
| gptkbp:discoveredBy |
Hiroyuki Mano
|
| gptkbp:discoveredIn |
2007
|
| gptkbp:firstDescribed |
Japanese population
|
| gptkbp:hasVariant |
variant 1
variant 2 variant 3a/b |
| https://www.w3.org/2000/01/rdf-schema#label |
EML4-ALK fusion
|
| gptkbp:involvedIn |
gptkb:ALK
gptkb:EML4 |
| gptkbp:locatedOnChromosome |
chromosome 2p21-p23
|
| gptkbp:mechanismOfAction |
fusion protein with constitutive kinase activity
|
| gptkbp:oncogenicDriver |
true
|
| gptkbp:prevalenceInNSCLC |
3-7%
|
| gptkbp:result |
chromosomal inversion
|
| gptkbp:significance |
predictive biomarker for ALK inhibitor therapy
|
| gptkbp:targetOfDrug |
gptkb:alectinib
gptkb:brigatinib gptkb:ceritinib gptkb:crizotinib gptkb:lorlatinib |
| gptkbp:bfsParent |
gptkb:EML4
|
| gptkbp:bfsLayer |
6
|